Journal article

Is CHEK2 a moderate-risk breast cancer gene or the younger sister of Li-Fraumeni?

Dilanka L De Silva, Ingrid Winship

BMJ Case Reports | BMJ Publishing Group | Published : 2020

Abstract

The CHEK2 gene is mostly considered as a moderate breast cancer gene with the result that many clinicians have a narrow focus. We present the 10-year journey of a man who had five different cancers and had iterative genetic testing including for Li-Fraumeni syndrome, eventually to discover a pathogenic variant in the CHEK2 gene, possibly explaining his numerous cancers. This diagnosis offered him closure which he had desperately sought for well over a decade. A pathogenic variant in the CHEK2 gene can potentially explain these cancers because of its function as a tumour suppressor gene. Consideration is warranted of what this means for individuals with CHEK2 variants who may develop multiple..

View full abstract